Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003555895 | SCV004298002 | likely pathogenic | not provided | 2023-01-12 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This sequence change affects a donor splice site in intron 6 of the ADAMTS10 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ADAMTS10 are known to be pathogenic (PMID: 15368195, 18567016). This variant is present in population databases (rs387906266, gnomAD 0.01%). Disruption of this splice site has been observed in individual(s) with Weill-Marchesani syndrome (PMID: 15368195). ClinVar contains an entry for this variant (Variation ID: 1946). |
OMIM | RCV000002023 | SCV000022181 | pathogenic | Weill-Marchesani syndrome 1 | 2004-11-01 | no assertion criteria provided | literature only |